The results showed that, in contrast to dasatinib, the addition of both regorafenib and rebastinib effectively restored the IFN-γ production by tumor-specific T cells inactivated by ANGPT2 exposition (Figure 4F). This evidence concerns the gene IFNG and neoplasm.